FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1135-1138 April 25, 1996 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Swartz, M. N. Related Article by McKenzie, R.

To the Editor: The report by McKenzie et al. (Oct. 26 issue)¹ entitled "Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B" is deeply troubling to those who treat chronic viral infections with nucleoside analogues. I am particularly concerned by the selection of some of the patients in the study. According to the text, only 8 of the 15 patients (all of whom had uncomplicated chronic hepatitis B and were positive for hepatitis B surface antigen and e antigen) had been previously treated with interferon, and some had received other nucleoside analogues . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.